vs
Side-by-side financial comparison of IDEX Corporation (IEX) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($619.8M vs $398.4M, roughly 1.6× IDEX Corporation). IDEX Corporation runs the higher net margin — 30.1% vs -14.8%, a 44.9% gap on every dollar of revenue. On growth, IDEX Corporation posted the faster year-over-year revenue change (16.7% vs -10.5%). Over the past eight quarters, QuidelOrtho Corp's revenue compounded faster (-6.6% CAGR vs -29.4%).
IDEX can refer to several things, including:International Defence Exhibition, a biennial arms and defense technology sales exhibition IDEX Corporation, a publicly listed company that makes fluidics systems and specialty engineered products Ideanomics, a publicly traded company that trades under the IDEX ticker symbol.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
IEX vs QDEL — Head-to-Head
Income Statement — Q2 FY2026 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $398.4M | $619.8M |
| Net Profit | $120.0M | $-91.8M |
| Gross Margin | 99.9% | — |
| Operating Margin | 43.3% | — |
| Net Margin | 30.1% | -14.8% |
| Revenue YoY | 16.7% | -10.5% |
| Net Profit YoY | 25.7% | — |
| EPS (diluted) | $1.61 | $-1.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | $398.4M | — | ||
| Q1 26 | $407.7M | $619.8M | ||
| Q4 25 | $899.1M | — | ||
| Q3 25 | $878.7M | $699.9M | ||
| Q2 25 | $865.4M | $613.9M | ||
| Q1 25 | $814.3M | $692.8M | ||
| Q4 24 | $862.9M | $707.8M | ||
| Q3 24 | $798.2M | $727.1M |
| Q2 26 | $120.0M | — | ||
| Q1 26 | $128.3M | $-91.8M | ||
| Q4 25 | $128.3M | — | ||
| Q3 25 | $127.8M | $-733.0M | ||
| Q2 25 | $131.6M | $-255.4M | ||
| Q1 25 | $95.5M | $-12.7M | ||
| Q4 24 | $123.2M | $-178.4M | ||
| Q3 24 | $119.1M | $-19.9M |
| Q2 26 | 99.9% | — | ||
| Q1 26 | 94.9% | — | ||
| Q4 25 | 43.1% | — | ||
| Q3 25 | 44.5% | — | ||
| Q2 25 | 45.3% | — | ||
| Q1 25 | 45.3% | — | ||
| Q4 24 | 42.5% | — | ||
| Q3 24 | 44.3% | — |
| Q2 26 | 43.3% | — | ||
| Q1 26 | 45.0% | — | ||
| Q4 25 | 20.4% | — | ||
| Q3 25 | 21.1% | -100.7% | ||
| Q2 25 | 21.7% | -29.4% | ||
| Q1 25 | 17.4% | 4.7% | ||
| Q4 24 | 19.2% | -14.2% | ||
| Q3 24 | 21.0% | 2.1% |
| Q2 26 | 30.1% | — | ||
| Q1 26 | 31.5% | -14.8% | ||
| Q4 25 | 14.3% | — | ||
| Q3 25 | 14.5% | -104.7% | ||
| Q2 25 | 15.2% | -41.6% | ||
| Q1 25 | 11.7% | -1.8% | ||
| Q4 24 | 14.3% | -25.2% | ||
| Q3 24 | 14.9% | -2.7% |
| Q2 26 | $1.61 | — | ||
| Q1 26 | $1.71 | $-1.35 | ||
| Q4 25 | $1.71 | — | ||
| Q3 25 | $1.70 | $-10.78 | ||
| Q2 25 | $1.74 | $-3.77 | ||
| Q1 25 | $1.26 | $-0.19 | ||
| Q4 24 | $1.61 | $-2.54 | ||
| Q3 24 | $1.57 | $-0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $586.2M | $140.4M |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | $4.0B | $1.9B |
| Total Assets | $6.9B | $5.6B |
| Debt / EquityLower = less leverage | — | 1.33× |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $586.2M | — | ||
| Q1 26 | $580.0M | $140.4M | ||
| Q4 25 | $580.0M | — | ||
| Q3 25 | $593.8M | $98.1M | ||
| Q2 25 | $568.2M | $151.7M | ||
| Q1 25 | $594.1M | $127.1M | ||
| Q4 24 | $620.8M | $98.3M | ||
| Q3 24 | $633.2M | $143.7M |
| Q2 26 | — | — | ||
| Q1 26 | — | $2.5B | ||
| Q4 25 | $1.8B | — | ||
| Q3 25 | $1.9B | $2.5B | ||
| Q2 25 | $1.9B | $2.1B | ||
| Q1 25 | $2.0B | $2.1B | ||
| Q4 24 | $2.0B | $2.1B | ||
| Q3 24 | $2.1B | $2.2B |
| Q2 26 | $4.0B | — | ||
| Q1 26 | $4.0B | $1.9B | ||
| Q4 25 | $4.0B | — | ||
| Q3 25 | $4.0B | $2.0B | ||
| Q2 25 | $4.0B | $2.8B | ||
| Q1 25 | $3.9B | $3.0B | ||
| Q4 24 | $3.8B | $3.0B | ||
| Q3 24 | $3.8B | $3.2B |
| Q2 26 | $6.9B | — | ||
| Q1 26 | $6.9B | $5.6B | ||
| Q4 25 | $6.9B | — | ||
| Q3 25 | $7.0B | $5.7B | ||
| Q2 25 | $6.9B | $6.4B | ||
| Q1 25 | $6.8B | $6.5B | ||
| Q4 24 | $6.7B | $6.4B | ||
| Q3 24 | $7.0B | $6.8B |
| Q2 26 | — | — | ||
| Q1 26 | — | 1.33× | ||
| Q4 25 | 0.45× | — | ||
| Q3 25 | 0.48× | 1.23× | ||
| Q2 25 | 0.46× | 0.74× | ||
| Q1 25 | 0.50× | 0.70× | ||
| Q4 24 | 0.52× | 0.72× | ||
| Q3 24 | 0.55× | 0.68× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | — |
| Free Cash FlowOCF − Capex | $86.0M | — |
| FCF MarginFCF / Revenue | 21.6% | — |
| Capex IntensityCapex / Revenue | 4.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $654.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $209.5M | — | ||
| Q3 25 | $203.5M | $-45.5M | ||
| Q2 25 | $161.7M | $-46.8M | ||
| Q1 25 | $105.7M | $65.6M | ||
| Q4 24 | $172.6M | $63.7M | ||
| Q3 24 | $205.3M | $117.9M |
| Q2 26 | $86.0M | — | ||
| Q1 26 | $189.8M | — | ||
| Q4 25 | $189.8M | — | ||
| Q3 25 | $188.7M | $-94.7M | ||
| Q2 25 | $146.9M | $-84.3M | ||
| Q1 25 | $91.4M | $9.4M | ||
| Q4 24 | $157.1M | $16.5M | ||
| Q3 24 | $191.6M | $71.4M |
| Q2 26 | 21.6% | — | ||
| Q1 26 | 46.6% | — | ||
| Q4 25 | 21.1% | — | ||
| Q3 25 | 21.5% | -13.5% | ||
| Q2 25 | 17.0% | -13.7% | ||
| Q1 25 | 11.2% | 1.4% | ||
| Q4 24 | 18.2% | 2.3% | ||
| Q3 24 | 24.0% | 9.8% |
| Q2 26 | 4.4% | — | ||
| Q1 26 | 15.6% | — | ||
| Q4 25 | 2.2% | — | ||
| Q3 25 | 1.7% | 7.0% | ||
| Q2 25 | 1.7% | 6.1% | ||
| Q1 25 | 1.8% | 8.1% | ||
| Q4 24 | 1.8% | 6.7% | ||
| Q3 24 | 1.7% | 6.4% |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.63× | — | ||
| Q3 25 | 1.59× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 1.11× | — | ||
| Q4 24 | 1.40× | — | ||
| Q3 24 | 1.72× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IEX
Segment breakdown not available.
QDEL
| Labs | $353.1M | 57% |
| Immunohematology | $138.3M | 22% |
| Point of Care | $112.8M | 18% |
| Molecular Diagnostics | $7.8M | 1% |
